Analysis of factors related to ovarian function damage in patients with systemic lupus erythematosus or Takayasu arteritis receiving cyclophosphamide therapy
10.3760/cma.j.issn.1008-5734.2015.06.007
- VernacularTitle:环磷酰胺致系统性红斑狼疮及大动脉炎患者卵巢功能受损的相关因素分析
- Author:
Qiuju LIAO
1
;
Zheng ZHENG
;
Yi ZHAO
;
Xiaoxia LI
Author Information
1. 首都医科大学宣武医院风湿免疫科, 北京,100053
- Publication Type:Journal Article
- Keywords:
Cyclophosphamide;
Lupus erythematosus,systemic;
Takayasu arteritis;
Ovarian diseases
- From:
Adverse Drug Reactions Journal
2015;(6):428-432
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the factors related to ovarian injury after cyclophosphamide therapy in the patients with systemic lupus erythematosus(SLE)and Takayasu arteritis(TA). Methods Data of patients with SLE and TA hospitalized in Xuanwu Hospital of Capital Medical University from June 2012 to October 2014 were collected and a retrospective study was conducted. All patients received cyclophosphamide treatment and were followed up in the outpatient setting. The patients with SLE who used cyclophosphamide treatment were divided into SLE group and the patients with TA who used cyclophosphamide treatment were divided into TA group. The overall incidence of ovarian injury,the incidence of amenorrhea and the time after cyclophosphamide treatment and the cumulative dosage which led to ovarian injury and amenorrhea were recorded and compared. Results Sixty-three patients were enrolled,46 cases were in SLE group,ages ranged from 15 to 41years;17 cases were in TA group,ages ranged from 17 to 37 years. Two groups of patients with ovarian injury after cyclophosphamide occurred mainly from 20 to 39 years. The overall incidence of ovarian injury and incidence of amenorrhea in two groups had no statistically significant difference[60. 9%(28 / 46)vs. 35. 3%(6 / 17),19. 6%(9 / 46)vs. 5. 9%(1 / 17),all P > 0. 05]. The ovarian injury in SLE group occurred in week 6 after cyclophosphamide treatment,the average time was 13 weeks. In TA group ovarian injury occurred in week 16,the average time was 21 weeks. Ovarian injury occurred earlier in SLE group than that in TA group,the difference was statistically significant(P = 0. 021). The cumulative dose of cyclophosphamide in SLE group was lower than that the TA group[(7. 2 ± 0. 8)g vs.(8. 0 ± 0. 9)g],the difference was statistically significant(P =0. 045). The cumulative dose of cyclophosphamide and the age showed a negative correlation(SLE group r = - 0. 681,P = 0. 028;TA group r = - 0. 244,P = 0. 043). Conclusions The cumulative dose of cyclophosphamide in patients with SLE and TA is a risk factor for ovarian injury. The cumulative dose of cyclophosphamide in SLE patients was less than patients with TA. The older patient who use cyclophosphamide initially are at greater risk of ovarian injury.
